市場調査レポート
商品コード
1084472
リバーロキサバンの世界市場:規模、シェア、動向、予測(2022年~2028年)Rivaroxaban Market - Size, Share, Trends, and Forecast, 2022 - 2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
リバーロキサバンの世界市場:規模、シェア、動向、予測(2022年~2028年) |
出版日: 2022年05月24日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2~3営業日
|
世界のリバーロキサバンの市場規模は、適応症拡大のための臨床試験の増加などによって促進されています。一方で、薬剤の副作用や代替療法が予測期間中の同市場の成長を抑制する可能性があります。
当レポートでは、世界のリバーロキサバン市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、製品タイプ・用途・地域別の分析、および競合情勢などを提供しています。
Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.
Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.
This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics
The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly
Global Rivaroxaban Market, By Strength:
10 mg
15 mg
20 mg
Global Rivaroxaban Market, By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
Global Rivaroxaban Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Rivaroxaban Market, By Region:
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
Germany
U.K.
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
GCC
Israel
Rest of Middle East
Africa
By Strength:
10 mg
15 mg
20 mg
By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By country:
North Africa
Central Africa
South Africa
Company Profiles
Janssen Pharmaceuticals Inc.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.